LU91313I2 - Combinaison de particules viroides de la protéine L1 recombinante du papillomavirus de type 6, 11, 16 et 18 - Google Patents

Combinaison de particules viroides de la protéine L1 recombinante du papillomavirus de type 6, 11, 16 et 18

Info

Publication number
LU91313I2
LU91313I2 LU91313C LU91313C LU91313I2 LU 91313 I2 LU91313 I2 LU 91313I2 LU 91313 C LU91313 C LU 91313C LU 91313 C LU91313 C LU 91313C LU 91313 I2 LU91313 I2 LU 91313I2
Authority
LU
Luxembourg
Prior art keywords
protein
combination
recombinant papillomavirus
viroid particles
cell
Prior art date
Application number
LU91313C
Other languages
English (en)
Original Assignee
Univ Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26703787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91313(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/028,517 external-priority patent/US8062642B1/en
Application filed by Univ Rochester filed Critical Univ Rochester
Publication of LU91313I2 publication Critical patent/LU91313I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
LU91313C 1993-03-09 2007-02-21 Combinaison de particules viroides de la protéine L1 recombinante du papillomavirus de type 6, 11, 16 et 18 LU91313I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/028,517 US8062642B1 (en) 1993-03-09 1993-03-09 Production of papillomavirus capsid protein and virus-like particles
US20730994A 1994-03-07 1994-03-07
PCT/US1994/002443 WO1994020137A1 (fr) 1993-03-09 1994-03-08 Production de proteine de capside de virus du papillome humain et particules de type viral

Publications (1)

Publication Number Publication Date
LU91313I2 true LU91313I2 (fr) 2007-04-23

Family

ID=26703787

Family Applications (3)

Application Number Title Priority Date Filing Date
LU91313C LU91313I2 (fr) 1993-03-09 2007-02-21 Combinaison de particules viroides de la protéine L1 recombinante du papillomavirus de type 6, 11, 16 et 18
LU91391C LU91391I2 (fr) 1993-03-09 2007-12-14 "La combinaison de particules viroïdes de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" Cervarix
LU91392C LU91392I2 (fr) 1993-03-09 2007-12-14 "La particule viroïde de la protéine L1 recombinante du papillomavirus humain de type 16" - Cervarix

Family Applications After (2)

Application Number Title Priority Date Filing Date
LU91391C LU91391I2 (fr) 1993-03-09 2007-12-14 "La combinaison de particules viroïdes de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" Cervarix
LU91392C LU91392I2 (fr) 1993-03-09 2007-12-14 "La particule viroïde de la protéine L1 recombinante du papillomavirus humain de type 16" - Cervarix

Country Status (13)

Country Link
EP (3) EP1588713B1 (fr)
JP (4) JPH08507685A (fr)
AT (3) ATE296111T1 (fr)
AU (3) AU688759C (fr)
CA (1) CA2157932C (fr)
DE (9) DE69434383T2 (fr)
DK (2) DK0688227T3 (fr)
ES (3) ES2263406T3 (fr)
FR (1) FR11C0022I2 (fr)
LU (3) LU91313I2 (fr)
NL (3) NL300265I2 (fr)
PT (2) PT688227E (fr)
WO (1) WO1994020137A1 (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1359156B1 (fr) 1991-07-19 2007-03-07 University of Queensland Vaccin contre le Papillomavirus Humain (Type 18)
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
AUPM358894A0 (en) * 1994-01-31 1994-02-24 Csl Limited Modified papilloma virus l2 protein and vlps formed therefrom
DE4415743C2 (de) 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AU2003235191B2 (en) * 1994-10-07 2006-09-21 Loyola University Of Chicago Papilloma virus-like particles, fusion proteins as well as processes for their production
EP1728800A1 (fr) * 1994-10-07 2006-12-06 Loyola University Of Chicago Particules semblables au virus du papillome, protéines de fusion et leur procédé de production
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
AU4727296A (en) * 1995-02-24 1996-09-11 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5820870A (en) * 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
ES2213185T3 (es) * 1995-11-15 2004-08-16 MERCK & CO., INC. Particulas de tipo virus hpv11 sinteticas.
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
US6908615B1 (en) 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
ES2210587T3 (es) * 1996-10-04 2004-07-01 MERCK & CO., INC. (A NEW JERSEY CORP.) Particulas sinteticas tipo virus hpv16.
EP0948351B1 (fr) * 1996-12-09 2004-02-25 Merck & Co., Inc. Particules synthetiques de nature virale de type hpv16
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
CA2229955C (fr) 1998-02-20 2003-12-09 Medigene Gmbh Formulations de vaccins contenant des capsomeres de papillomavirus; methodes d'utilisation
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
AU2001294565A1 (en) * 2000-09-18 2002-04-02 Med Immune, Inc. In vitro assay for measuring the immunogenicity of a vaccine
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
AU2002367977B2 (en) 2001-08-13 2008-06-19 University Of Rochester Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
ES2356154T3 (es) 2003-07-21 2011-04-05 Transgene S.A. Citoquinas multifuncionales.
WO2006113209A1 (fr) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procedes et compositions permettant de produire une reponse immunitaire amelioree contre un immunogene papillomavirus humain
WO2006065166A1 (fr) * 2005-07-26 2006-06-22 Obschestvo S Ogranichennoi Otvetstvennostyu 'rusgen' Composition de traitement et de prevention de l'infection de l'humain par le papillomavirus sur la base de la proteine l1 et des peptides de la proteine e7
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8778351B2 (en) 2006-08-30 2014-07-15 University Of Rochester Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2468300B1 (fr) 2006-09-26 2017-12-20 Infectious Disease Research Institute Composition de vaccin contenant un adjuvant synthétique
CN103550764A (zh) 2007-03-02 2014-02-05 葛兰素史密丝克莱恩生物有限公司 疫苗组合物及其在刺激免疫反应中的用途
EP2154147B1 (fr) * 2007-04-29 2015-10-07 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Protéine l1 tronquée du papillomavirus 16 humain
EP2147926B1 (fr) 2007-04-29 2016-08-24 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Protéines 18 l1 de type papillomavirus humain tronque
US9533035B2 (en) 2007-05-29 2017-01-03 Xiamen University Truncated L1 protein of human papillomavirus type 11
EP2154149B1 (fr) 2007-05-29 2019-07-10 Xiamen University Proteine l1 tronquee du papillomavirus humain de type 6
WO2009092113A2 (fr) * 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methodes et compositions d'administration de vaccins dans un epithelium rompu
BRPI0909547A2 (pt) 2008-05-26 2019-03-06 Cadila Healthcare Ltd. vacina combinada de sarampo - hpv, vetor e hospedero
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
US20120115207A1 (en) * 2009-04-03 2012-05-10 Deutsches Krebsforschungszentrum Enhanced production of papillomavirus-like particles with a modified baculovirus expression system
CA2764374C (fr) 2009-06-05 2019-11-19 Infectious Disease Research Institute Adjuvants lipidiques synthetiques a base de glucopyranosyle
WO2011026111A1 (fr) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Distribution par voie orale d'un vaccin au gros intestin pour induire une immunité mucosale
EP3730943B1 (fr) 2010-04-08 2025-01-29 University of Pittsburgh - Of the Commonwealth System of Higher Education Analyse de cellules présentatrices d'antigène des lymphocytes b
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
CN104203270A (zh) 2012-03-18 2014-12-10 葛兰素史密丝克莱恩生物有限公司 针对人乳头状瘤病毒的接种方法
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
JP6430949B2 (ja) 2012-10-23 2018-11-28 エモリー ユニバーシティ Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
CA2909221A1 (fr) 2013-04-18 2014-10-23 Immune Design Corp. Monotherapie par gla pour une utilisation dans le traitement du cancer
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
WO2017144359A1 (fr) 2016-02-22 2017-08-31 Boehringer Ingelheim Vetmedica Gmbh Procédé d'immobilisation de biomolécules
KR102483033B1 (ko) 2016-05-16 2022-12-30 액세스 투 어드밴스드 헬스 인스티튜트 페길화된 리포솜 및 이의 용도
RU2761870C2 (ru) 2016-05-16 2021-12-13 Инфекшес Дизис Рисёрч Инститьют Состав, содержащий агонист tlr, и способы применения
EP3463300A1 (fr) 2016-06-01 2019-04-10 Infectious Disease Research Institute Nanoparticules d'alun contenant un agent d'encollage
AU2018285694B2 (en) 2017-06-15 2025-04-10 Access To Advanced Health Institute Nanostructured lipid carriers and stable emulsions and uses thereof
EP3678695A1 (fr) 2017-09-08 2020-07-15 Infectious Disease Research Institute Formulations liposomales comprenant de la saponine et procédés d'utilisation
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
US20230310323A1 (en) 2020-09-04 2023-10-05 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
MX2023009456A (es) 2021-02-11 2023-08-28 Glaxosmithkline Biologicals Sa Preparacion de la vacuna contra el vph.
WO2024052882A1 (fr) 2022-09-09 2024-03-14 Access To Advanced Health Institute Composition de vaccin immunogène incorporant une saponine
CN116375816B (zh) * 2023-01-06 2023-09-05 北京康乐卫士生物技术股份有限公司 一种人乳头瘤病毒56型l1蛋白突变体及减少重组蛋白降解的方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956288A (en) * 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
NZ232913A (en) 1989-03-15 1992-08-26 Gist Brocades Nv Il-3 produced recombinantly and purified to homogeneity; vectors and pharmaceutical preparations
EP1359156B1 (fr) * 1991-07-19 2007-03-07 University of Queensland Vaccin contre le Papillomavirus Humain (Type 18)

Also Published As

Publication number Publication date
EP1618888B1 (fr) 2011-01-05
AU2007201006B2 (en) 2010-07-01
DK0688227T3 (da) 2005-06-27
ES2263406T1 (es) 2006-12-16
LU91391I2 (fr) 2008-02-14
FR11C0022I1 (fr) 2011-05-08
ES2263406T3 (es) 2011-06-06
JP2010148514A (ja) 2010-07-08
AU6443694A (en) 1994-09-26
JP5386392B2 (ja) 2014-01-15
JP4486075B2 (ja) 2010-06-23
PT1618888E (pt) 2011-04-08
ES2242955T3 (es) 2005-11-16
NL300310I1 (nl) 2008-02-01
DE69434383T2 (de) 2005-11-24
ES2263405T1 (es) 2006-12-16
CA2157932C (fr) 2011-10-11
ES2242955T4 (es) 2010-04-12
NL300309I1 (nl) 2008-02-01
DE122007000090I1 (de) 2008-03-27
DE122007000014I1 (de) 2007-05-24
EP1588713B1 (fr) 2010-12-22
FR11C0022I2 (fr) 2012-08-03
AU2007201006A1 (en) 2007-03-29
JP5306251B2 (ja) 2013-10-02
EP0688227A4 (fr) 1996-05-29
DE69434383D1 (de) 2005-06-30
HK1082196A1 (en) 2006-06-02
ATE492289T1 (de) 2011-01-15
AU2007201005A1 (en) 2007-03-29
DE05075369T1 (de) 2006-11-16
DK1618888T3 (da) 2011-04-04
NL300265I2 (nl) 2008-05-01
ES2263405T3 (es) 2011-04-20
CA2157932A1 (fr) 1994-09-15
EP1588713A1 (fr) 2005-10-26
JP2007075117A (ja) 2007-03-29
DE69435332D1 (de) 2011-02-17
DE122007000089I1 (de) 2008-03-27
PT688227E (pt) 2005-10-31
ATE296111T1 (de) 2005-06-15
JP2010099091A (ja) 2010-05-06
HK1082206A1 (en) 2006-06-02
AU2007201005B2 (en) 2010-06-10
DE05075889T1 (de) 2006-10-05
DE122011100018I1 (de) 2011-11-17
DE69435331D1 (de) 2011-02-03
LU91392I2 (fr) 2008-02-14
JPH08507685A (ja) 1996-08-20
EP0688227B1 (fr) 2005-05-25
NL300309I2 (nl) 2008-03-03
NL300265I1 (nl) 2007-05-01
EP1618888A1 (fr) 2006-01-25
ATE494005T1 (de) 2011-01-15
AU688759C (en) 2006-12-21
EP0688227A1 (fr) 1995-12-27
WO1994020137A1 (fr) 1994-09-15
AU688759B2 (en) 1998-03-19

Similar Documents

Publication Publication Date Title
LU91391I2 (fr) "La combinaison de particules viroïdes de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" Cervarix
DK0809700T3 (da) Papillomaviruslignende partikler, fusionsproteiner samt fremgangsmåde til fremstilling heraf
DE69535018D1 (de) Papillomavirus vakzine
EA199700281A1 (ru) Молекула днк, кодирующая белок l1 вируса папилломы типа 11 чепловека, экспрессирующий вектор, способ получения очищенных вирусоподобных частиц
ATE91630T1 (de) Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren.
DK0750669T3 (da) Modificeret papillomavirus-L2-protein og VLP'er dannet derudfra
DE69829174D1 (de) Exprimierung eines modifiziertem "foamy virus envelope protein" (hüllenprotein)